{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:54:45Z","timestamp":1761562485668},"reference-count":19,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Asthma"],"published-print":{"date-parts":[[2020,5,3]]},"DOI":"10.1080\/02770903.2019.1579833","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T06:28:52Z","timestamp":1550903332000},"page":"521-524","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center\u2019s early clinical experience"],"prefix":"10.1080","volume":"57","author":[{"given":"Elise","family":"Weir","sequence":"first","affiliation":[{"name":"Department of Respiratory Paediatrics, Royal Hospital for Children Glasgow, Glasgow, United Kingdom of Great Britain and Northern Ireland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Paton","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Glasgow, Glasgow, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"CIT0001","first-page":"102","volume":"160","author":"Sorkness CA","year":"2013","journal-title":"J Allergy Clin Immumol Pract"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1321945"},{"key":"CIT0003","unstructured":"National Institute for Health and Care Excellence (2017) Mepolizumab for treating severe refractory eosinophilic asthma. NICE technology appraisal guidance (TA431)."},{"key":"CIT0004","unstructured":"Scottish Medicine Consortium (2016) Mepolizumab 100mg powder for solution for injection (Nucala\u00ae). SMC No. (1149\/16)."},{"key":"CIT0005","doi-asserted-by":"crossref","unstructured":"Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo controlled trial. Lancet 2012;380:651\u2013659.","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"CIT0008","volume-title":"European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma","author":"GlaxoSmithKline","year":"2018"},{"key":"CIT0009","unstructured":"GSK Clinical Study Report MEA115588. Available from: https:\/\/www.gsk-clinicalstudyregister.com\/files2\/gsk-115588-clinical-study-report-redact.pdf [last accessed July 2018]."},{"key":"CIT0010","unstructured":"GSK Clinical Study Report MEA 115575. Available from: https:\/\/www.gsk-clinicalstudyregister.com\/files2\/gsk-115575-clinical-study-report-redact.pdf [last accessed July 2018]."},{"key":"CIT0011","unstructured":"GSK Clinical Study Report MEA112997. Available from: https:\/\/www.gsk-clinicalstudyregister.com\/files2\/gsk-112997-clinical-study-report-redact.pdf [last accessed July 2018]."},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.008"},{"key":"CIT0013","unstructured":"National Institute for Health and Care Excellence (2013) Omalizumab for treating severe persistent allergic asthma. NICE technology appraisal guidance (TA278)."},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035005"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034905"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.06.007"}],"container-title":["Journal of Asthma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/02770903.2019.1579833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T22:59:09Z","timestamp":1598655549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02770903.2019.1579833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,3]]}},"alternative-id":["10.1080\/02770903.2019.1579833"],"URL":"https:\/\/doi.org\/10.1080\/02770903.2019.1579833","relation":{},"ISSN":["0277-0903","1532-4303"],"issn-type":[{"value":"0277-0903","type":"print"},{"value":"1532-4303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijas20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijas20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}